In vitro antibacterial activity of ME1207, a new oral cephalosporin.
ME1207 is the prodrug of ME1206. Its in vitro antibacterial activity was compared with that of cefteram, cefpodoxime, cefixime, and cefaclor against various clinical isolates. ME1206 was more active than the other cephems tested against staphylococci, streptococci, Morganella morganii, Pseudomonas cepacia, and Flavobacterium meningosepticum and had the most potent activity against Haemophilus influenzae and Neiserria gonorrhoeae. The drug also showed a wide spectrum of activity against other gram-positive and gram-negative bacteria, except methicillin-resistant Staphylococcus aureus, Enterococcus faecalis, Citrobacter freundii, Pseudomonas aeruginosa, Xanthomonas maltophilia, and Alcaligenes xylosoxydans.
Department of Microbiology, Toho University School of Medicine, Tokyo, Japan.
S
S
Miyazaki
Y
Y
Miyazaki
A
A
Tsuji
M
M
Nishida
S
S
Goto
D000284:Administration, Oral; D002511:Cephalosporins / Q000494:pharmacology*; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D011355:Prodrugs / Q000494:pharmacology*; D013211:Staphylococcus aureus / Q000187:drug effects
D002511:Cephalosporins; D011355:Prodrugs; C057710:cefditoren pivoxil